Advertisement Myriad signs diabetes research collaboration with Sanofi, PHRI - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Myriad signs diabetes research collaboration with Sanofi, PHRI

Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has signed diabetes research collaboration with Sanofi and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University.

According to the deal, Myriad will perform protein biomarker discovery on over 8,000 serum samples collected from patients with pre-diabetes or Type 2 Diabetes participating in Glargine Intervention (ORIGIN) study using its DiscoveryMAP 250+ quantitative immunoassay panel.

Myriad RBM president Craig Benson said, "We believe this collaboration will result in better care for millions of patients with diabetes; a global epidemic that remains a critical unmet medical need."

PHRI will assess the relationship between the biomarker results and clinical outcomes.

PHRI research laboratory director Dr. Matt McQueen said biomarker project which leverages DiscoveryMAP is a logical extension of the landmark ORIGIN study.

"The measurement of hundreds of relevant proteins in metabolic, inflammatory and other important pathways has the potential to improve treatment protocols for diabetes," Dr. McQueen added.